Fermenting next generation glycosylated therapeutics.
Mutants of glycosyltransferases and related sugar nucleotide biosynthetic enzymes have been essential for in vitro glycorandomization to create libraries of novel glycosylated natural products and derivatives. These diverse glycorandomized compounds can now be produced in vivo economically by fermenting engineered Escherichia coli cells that express enzyme mutants.
Department of Chemistry, University of California, Davis, 95616, United States. chen@chem.ucdavis.edu
Xi
X
Chen
D001688:Biological Products / Q000096:biosynthesis / Q000138:chemical synthesis; D053898:Biosynthetic Pathways; D002384:Catalysis; D004926:Escherichia coli / Q000201:enzymology* / Q000235:genetics* / Q000378:metabolism; D005285:Fermentation / Q000235:genetics* / Q000502:physiology; D006027:Glycosides / Q000235:genetics / Q000378:metabolism; D006031:Glycosylation; D016695:Glycosyltransferases / Q000235:genetics* / Q000378:metabolism*
D001688:Biological Products; D006027:Glycosides; D016695:Glycosyltransferases